NCEP/Framingham risk scores: Estimate of 10-yr CHD risk in men without CHD

Reilly MP, Rader DJ. Circulation. 2003;108:1546-51.

VBWG

Point total: <0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 >1710-yr risk (%) <1 1 1 1 1 1 2 2 3 4 5 6 8 10 12 16 20 25 ≥30

Age (y) 20–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79Points –9 –4 0 3 6 8 10 11 12 13

Systolic BP Points(mm Hg) Untreated Treated

<120 0 0120–129 0 1130–139 1 2140–159 1 2≥160 2 3

HDL-C (mg/dL) Points

≥60 –150–59 040–49 1<40 2

Age (y) 20–39 40–49 50–59 60–69 70–79

Nonsmoker 0 0 0 0 0Smoker 8 5 3 1 1

PointsTotal-C Age (y)(mg/dL) 20–39 40–49 50–59 60–69 70–79

<160 0 0 0 0 0160–199 4 3 2 1 0200–239 7 5 3 1 0240–279 9 6 4 2 1≥280 11 8 5 3 1

ATP III update: LDL-C goals and cutpointsfor treatment

Grundy SM et al. Circulation. 2004;110:227-39.

VBWG

*Diabetes or other noncoronary atherosclerotic disease†Favored for very high-risk subset‡No changes in moderate and lower-risk categoryTLC = therapeutic lifestyle change

Risk category LDL-C goal Initiate TLC Consider drug therapy

High risk: CHD or CHD risk <100 mg/dL ≥100 mg/dL ≥100 mg/dLequivalents*(10-yr risk >20%)

Moderately high risk: 2+ risk factors <130 mg/dL ≥130 mg/dL ≥130 mg/dL(10-yr risk 10%–20%)

Moderate risk‡: 2+ risk factors <130 mg/dL ≥130 mg/dL ≥160 mg/dL(10-yr risk <10%)

Lower risk‡: 0–1 risk factors <160 mg/dL ≥160 mg/dL ≥190 mg/dL

(160–189 mg/dLdrugs optional)

(optional goal:<70 mg/dL)†

(<100 mg/dL;consider drug options)

(optional goal:<100 mg/dL)

(100–129 mg/dL;consider drug options)